AMMI CONSENSUS PAPER

Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS

Richard G Lalonde MD FRCP1, Guy Boivin MD MSc FRCP2, Jean Deschênes MD FRCS3,
William G Hodge MD PhD FRCS4, J Jill Hopkins MD FRCS5, Alex H Klein MD6, Janette I Lindley MD FRCS7,
Peter Phillips MD8, Stephen D Shaffran MD9, Sharon Walmsley MD10

Reviewed by the AMMI Guidelines Committee:
G Evans, Chair; M Laverdiere; L Nicolle; P Phillips; C Quan; and C Rotstein

OBJECTIVES: These updated guidelines are intended to provide practical help to physicians managing HIV-positive patients with or at risk for CMV disease.

METHODS: The 10 members of the Canadian CMV Disease in HIV/AIDS Consensus Group were infectious disease specialists, a primary care physician and ophthalmologists with expertise in HIV and CMV infection. Financial support by Hoffmann-La Roche Canada Ltd was unrestricted, and was limited to travel expenses and honoraria. The consensus group met in June and October 2002. Key areas to be considered were identified, and group members selected, reviewed and presented relevant recent literature for their assigned section for the group’s consideration. Evidence was assessed based on established criteria, which were expert opinions of the members. Draft documents were circulated to the entire group and modified until consensus was reached. The final guidelines represent the group’s consensus agreement. The guidelines were expert opinions of the members. Draft documents were circulated to the entire group and modified until consensus was reached. The final guidelines were approved by the Canadian Infectious Disease Society.

RESULTS AND CONCLUSIONS: The guidelines address symptom monitoring, screening for early detection and prevention, and treatment using oral, intravenous and intraocular anti-CMV therapies in conjunction with HAART.

Key Words: Cytomegalovirus disease; Diagnosis; Guidelines; HIV/AIDS; Screening; Treatment

HISTORIQUE: Le traitement des patients VIH-positifs infectés par le cytomegalovirus (CMV) a significativement changé depuis l’avènement des schémas antirétroviraux hautement actifs ou HAART (pour highly active antiretroviral therapy).

OBJECTIF: Avec cette mise à jour des directives, le groupe d’expert espère venir en aide aux médecins qui soignent des patients VIH-positifs souffrant ou risquant de souffrir de maladie à CMV.

MÉTHODES: Au nombre de dix, les membres du groupe d’experts canadiens sur la maladie à CMV dans le contexte du VIH/sida comprenaient des infectiologues, un médecin de premier recours et des ophtalmologistes, tous spécialistes de l’infection au VIH et au CMV. Le soutien financier de Hoffmann-La Roche Canada Inc. a été offert sans restriction et a couvert exclusivement les frais de déplacements et les honoraires des experts. Le groupe s’est rencontré en juin, puis en octobre 2002. Les domaines jugés importants ont été identifiés et les membres ont sélectionné, analysé et présenté au groupe les articles scientifiques récents pertinents sur les thèmes qui leur avaient été assignés. La qualité des preuves a été évaluée en fonction de critères établis et tenait compte de l’opinion experte des membres. Des ébauches ont circulé au sein de tout le groupe et ont été modifiées jusqu’à l’atteinte d’un consensus, reflété dans les directives finales. Ces directives ont reçu l’aval de la Société canadienne des maladies infectieuses.

RÉSULTATS ET CONCLUSION: Les directives portent sur la surveillance des symptômes, le dépistage de la maladie, sa prévention précoce et son traitement à l’aide d’agents anti-CMV oraux, intraveineux et intra-oculaires, alliés à une HAART.

©2004 Pulsus Group Inc. All rights reserved
Cytomegalovirus (CMV) infection is lifelong, typically acquired in childhood or adolescence, and usually asymptomatic. When T lymphocyte dysfunction occurs, CMV can reactivate and lead to disease (1,2). Before the advent of highly active antiretroviral therapy (HAART) for HIV infection, the most common CMV disease site was the retina, followed by the gastrointestinal (GI) tract and, less frequently, the central nervous system and respiratory tract (3).

Two major risk factors for CMV disease are CMV seropositivity and a low CD4 cell count (3,4). Other factors also play a role (Table 1). Before HAART, most patients had CD4 counts less than 100 cells/µL, and 75% to 80% of cases occurred in patients with CD4 counts less than 50/µL (4,5). The risk for CMV retinitis in patients with a CD4 count less than 100 cells/µL was 25% over four years (4). In the post-HAART era, CMV disease can occur in patients with higher CD4 counts within the first two months of HAART if they have a pretreatment CD4 count less than 100 cells/µL (6). The incidence of CMV retinitis in HIV-positive patients has declined by 55% to 80% since HAART was introduced (7,8).

Pre-HAART progression of CMV retinitis, if left untreated, destroyed the retina and led to blindness within six months (7,9). Even with treatment, the outcome of CMV retinitis was poor because of frequent relapses, sometimes complicated by retinal detachment (10). Today, some clinical manifestations of CMV disease have changed (7), but outcomes are far better because patients receive both anti-CMV therapy and HAART (11,12), and the resulting immune reconstitution helps to keep the CMV infection quiescent (6).

Updated guidelines for the management of CMV disease in patients with HIV infection are needed for three reasons. First, clinical expertise with CMV disease has decreased due to retinal detachment (10). Today, some clinical manifestations of CMV disease have changed (7), but outcomes are far better because patients receive both anti-CMV therapy and HAART (11,12), and the resulting immune reconstitution helps to keep the CMV infection quiescent (6).

Updated guidelines for the management of CMV disease in patients with HIV infection are needed for three reasons. First, clinical expertise with CMV disease has decreased due to decreased incidence and relapse rates. Second, immune reconstitution due to HAART has modified the disease characteristics associated with CMV. Finally, the recent approval of an oral anti-CMV drug may result in increased involvement by community-based primary care physicians in the management of CMV disease.

To provide current guidance on the management of CMV disease in patients with HIV infection, a 10-member Canadian CMV Disease in HIV/AIDS Consensus Group was formed by inviting all infectious disease specialists and ophthalmologists in Canada with a significant HIV-related practice. The group consisted of those specialists who chose to participate and a community-based primary care physician with expertise in CMV and HIV infection. Meetings were held in June and October 2002. Areas to be discussed were identified, and group members reviewed and presented relevant recent literature for their assigned section to the group for discussion. The quality of the evidence used in the guidelines was graded according to a system developed by the Infectious Disease Society of America (Table 2) (13). Expert opinions of the group members were included as evidence. Draft documents were circulated to the entire group and modified until a consensus was reached. The final guidelines represent the group’s consensus agreement. The guidelines were approved by the Canadian Infectious Disease Society.

The recommendations contained in these guidelines are intended for use by health care providers who treat adults with HIV infection. These recommendations are not a substitute for the judgment of a physician experienced in treating HIV-related CMV disease.

### TABLE 1

<table>
<thead>
<tr>
<th>Risk factors for CMV disease</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV seropositivity</td>
<td>Shepp et al (3)</td>
</tr>
<tr>
<td>CD4 cell count nadir &lt;100 cells/µL</td>
<td>Galian et al (2)</td>
</tr>
<tr>
<td>Prior occurrence of opportunistic infections</td>
<td>Burke et al (54)</td>
</tr>
<tr>
<td>CMV viremia in polymorphonuclear leukocytes or plasma</td>
<td>Dodt et al (28), Casado et al (55), Spector et al (29), Walmsley et al (30)</td>
</tr>
<tr>
<td>HIV plasma viremia</td>
<td>Spector et al (29)</td>
</tr>
<tr>
<td>Prior retinal damage</td>
<td>Jacobson and Mills (56)</td>
</tr>
<tr>
<td>Previous CMV disease</td>
<td>Verbraak et al (31)</td>
</tr>
<tr>
<td>Lack of anti-CMV therapy</td>
<td>Spector et al (57)</td>
</tr>
<tr>
<td>Lack of highly active antiretroviral therapy (HAART)</td>
<td>Verbraak et al (14)</td>
</tr>
</tbody>
</table>

### TABLE 2

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Good evidence in support of a recommendation for use</td>
</tr>
<tr>
<td>B</td>
<td>Moderate evidence to support a recommendation for use</td>
</tr>
<tr>
<td>C</td>
<td>Poor evidence to support a recommendation for or against use</td>
</tr>
<tr>
<td>D</td>
<td>Moderate evidence to support a recommendation against use</td>
</tr>
<tr>
<td>E</td>
<td>Good evidence to support a recommendation against use</td>
</tr>
</tbody>
</table>

Categories reflecting the quality of evidence on which recommendations are based

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one properly randomized, controlled trial</td>
</tr>
<tr>
<td>II</td>
<td>Evidence from at least one well-designed clinical trial without randomization from cohort or case-controlled analytic studies (preferably from more than one centre), from multiple time-series studies, or from dramatic results in uncontrolled experiments</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees</td>
</tr>
</tbody>
</table>

Reprinted from reference 13 with permission

### DIAGNOSIS

Risk factors for CMV disease in HIV-infected patients should be taken into account in the diagnosis (Table 3). Patients who are not taking HAART and who have a CD4 count less than 100 cells/µL are at highest risk (evidence grade IIIB) (14), while those with a CD4 count less than 100 cells/µL despite HAART (evidence grade IIB) (12) or who fail HAART (evidence grade IIB) (12) are at moderate risk. Also at risk are those patients with a pre-HAART CD4 count nadir less than 100 cells/µL and any increase in CD4 count in response to HAART within two months of its initiation (evidence grade IIB) (6).
CMV retinitis
Patients may present with a loss of vision, blurred/cloudy vision, light flashes, floaters (spots that appear to drift in front of the eye) or scotomata (blind spots) (10,15). However, CMV retinitis can be asymptomatic (16). CMV retinitis is diagnosed by an eye care professional through examination of the dilated retina, including the periphery (10,17). Examination of the retina reveals necrosis, a hemorrhagic yellow-white infiltrate that follows the vascular pattern with little vitreous inflammation (10,17,18) (Figures 1A and 1B). In patients on HAART, CMV retinitis may be more subtle, with a more focal greyish and granular appearance and little or no hemorrhage (Figure 1C).

HIV-positive patients should be educated about the symptoms and consequences of CMV retinitis, and encouraged to report visual symptoms early.

Recommendations
• Prompt dilated ocular examination by an eye care professional is required for patients at risk for CMV retinitis who have visual symptoms (evidence grade IIA).
• If active retinitis is present, photographs or drawings should be used to monitor disease progression (evidence grade IIB) (10,19).

Immune recovery uveitis
Immune recovery uveitis (IRU) has emerged as a new clinical entity in patients treated successfully with HAART who previously had CMV retinitis. IRU is an intraocular inflammation in response to CMV antigens, not a reactivation of CMV retinitis (20). The incidence of IRU varies from 0.11/year to 0.83/year (21,22) and occurs weeks to months following HAART initiation (22). Patients may note blurred vision, floaters, a loss of visual acuity (22) or, sometimes, ocular pain. Eye examinations may show cystoid macular edema, epiretinal membrane, proliferative vitreoretinopathy, spontaneous vitreal hemorrhage, posterior subcapsular cataracts or persistent anterior chamber inflammation (23). Treatment with topical steroids alone often suffices.

Nonocular CMV Disease
The diagnosis of nonocular CMV disease is difficult because clinical manifestations are not specific and there are no simple
blood tests. Diagnosis is confirmed when typical intracellular CMV inclusions are seen or CMV antigens are demonstrated in a biopsy of the involved organ. Table 4 highlights the clinical presentation and laboratory indicators of several nonocular sites of CMV disease.

Recommendations

- Before initiating anti-CMV treatment, the diagnosis of CMV disease should be confirmed through detection of CMV inclusions or antigen on organ biopsy (evidence grade IIB) (24-26). Positive cultures or molecular tests from organ tissue alone are not sufficiently specific (evidence grade IID) (26).
- A positive test for CMV DNA in cerebrospinal fluid confirms neurological CMV disease (evidence grade IIA).
- When tissue biopsy is not feasible, tests for CMV replication in the blood, although less specific, should be used to improve the level of diagnostic certainty (evidence grade IIIB). However, the types and threshold values of assays are still debated.

SCREENING FOR CMV DISEASE

Laboratory screening

CMV seropositivity is highly prevalent in HIV-infected patients (80% to 95%) (3,4). Seropositivity does not distinguish between latent and active CMV disease. However, CMV seronegativity does rule out CMV disease (3).

CMV disease is usually preceded by CMV replication in blood, urine or saliva. In transplant recipients, the use of anti-CMV drugs when CMV reactivation is detected prevents the occurrence of end organ disease, a strategy called pre-emptive therapy (1). In asymptomatic HIV-infected patients, CMV reactivation identifies an increased risk for CMV disease (27-30), but the value of pre-emptive therapy in this patient population has not been established.

Recommendations

- Specific recommendations about use and frequency of tests for CMV replication for pre-emptive therapy cannot be made because of the absence of randomized, controlled clinical studies to support their use (evidence grade IIC).
- Blood CMV serology testing should be considered for HIV-positive, previously CMV-seronegative patients who may receive blood products (evidence grade IIIC), because CMV-negative or leukocyte-deficient blood products should be considered.

Ocular examinations and screening for CMV retinitis

CMV retinitis can be detected before it becomes symptomatic (16). While the consensus group felt that early detection may be beneficial, especially for high-risk patients (Table 3), there are no data to support a recommendation for routine ophthalmology screening examinations or for the appropriate interval between examinations in asymptomatic patients (evidence grade IIIC) (12,27).

Recommendations

- Due to increased risk of CMV retinitis, patients with extracocular CMV disease should receive an eye examination (evidence grade II A) (10,31).
TREATMENT OF CMV DISEASE

Anti-CMV drugs are virustatic, not virucidal. Therefore, the goal of CMV disease treatment is control of the disease. Treatment begins with higher induction doses and, for CMV retinitis, induction is followed by lower dose maintenance therapy. Systemic (oral, intravenous [IV]) and local (intraocular injections and implants) anti-CMV therapies are available. For CMV retinitis, therapeutic drug concentrations are achieved much more quickly with intraocular therapy than with systemic therapy, but systemic therapy prevents occurrence in the other eye and other organs (32,33).

CMV retinitis induction therapy

Until the advent of valganciclovir, CMV retinitis could only be treated by injectable or implantable drugs, requiring either an indwelling venous catheter, weekly intraocular injections,
or repeated use of drug-releasing implants into the vitreous cavity of the eye (32,34-36). Figure 2 is a treatment algorithm for the management of CMV retinitis.

Recommendations
• When the diagnosis of CMV retinitis is confirmed, therapy should be initiated immediately to prevent further retinal damage (evidence grade IA).
• If intraocular therapy is used, concomitant systemic therapy should still be considered to protect the other eye and other organs (evidence grade IIA) (11,32,33).
• Local intraocular therapy alone may be used when systemic therapy is contraindicated. It also may be considered for adjunctive treatment in severe or relapsed cases where the patient’s vision is in immediate danger (evidence grade IIIB).
• The recommended minimum duration of induction therapy is three weeks, followed by maintenance therapy once the CMV retinitis is quiescent (evidence grade IIA).
• Patients require weekly ophthalmological examinations until CMV retinitis is quiescent (evidence grade IIIA) (11).
• Oral valganciclovir is the induction therapy of choice based on its effectiveness, convenience, and the elimination of catheter-related complications of IV therapy (evidence grade IA) (Table 5) (32,37).
• If valganciclovir is contraindicated, alternatives include: IV ganciclovir (evidence grade IA) (38); IV foscarnet (38) or cidofovir (evidence grade IA) (39); and finally, intraocular ganciclovir implants (evidence grade IA) (33,40) or injections of ganciclovir (evidence grade IV) (36), foscarnet (evidence grade IV) (41) or fomivirsen (evidence grade IA) (Table 5) (42).
• Because immune recovery with HAART initiation may increase the severity of CMV or other opportunistic infections (eg, tuberculosis), it may be preferable to treat CMV disease first and, once it is quiescent, begin HAART (evidence grade IIIIC).
• Levels of blood CMV viral load can be used to monitor the response to anti-CMV therapy (43,44) and indicate the emergence of CMV drug resistance (evidence grade IIB) (44,45).

CMV retinitis maintenance therapy (secondary prophylaxis)
Maintenance therapy to delay progression is required in the treatment of CMV retinitis (32,36,46,47).

Recommendations
• Before lowering the anti-CMV therapy dose to maintenance levels, remission must be confirmed by an ophthalmological examination.
• Frequent eye examinations are recommended to monitor the disease and detect relapse and development of IRU (evidence grade IV) (11,21). The frequency of

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Medication</th>
<th>Dose*</th>
<th>Evidence level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Induction therapy†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended therapy</td>
<td>Valganciclovir (32)</td>
<td>900 mg by mouth twice a day</td>
<td>IA</td>
</tr>
<tr>
<td>Alternative therapies</td>
<td>IV ganciclovir (38)</td>
<td>5 mg/kg IV twice a day</td>
<td>IA</td>
</tr>
<tr>
<td></td>
<td>IV foscarnet or IV cidofovir</td>
<td>IV foscarnet, 60 mg/kg every 8 h or</td>
<td>IA</td>
</tr>
<tr>
<td></td>
<td>(38,39)</td>
<td>90 mg/kg to 100 mg/kg every 12 h</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ganciclovir intraocular implant (40)</td>
<td>Implanted (release rate 1 µg/h to 2 µg/h) every six to nine months</td>
<td>IA</td>
</tr>
<tr>
<td>Intraocular injections</td>
<td>• Ganciclovir (58)</td>
<td>0.4 mg twice weekly</td>
<td>IIB</td>
</tr>
<tr>
<td></td>
<td>• Foscarnet (41)</td>
<td>2.4 mg every three days</td>
<td>IIB</td>
</tr>
<tr>
<td></td>
<td>• Fomivirsen (42)</td>
<td>165 µg every week for three weeks</td>
<td>IA</td>
</tr>
<tr>
<td>Maintenance therapy‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended therapy</td>
<td>Valganciclovir (32,46)</td>
<td>900 mg once daily</td>
<td>IA</td>
</tr>
<tr>
<td>Alternative therapies</td>
<td>Ganciclovir IV (38)</td>
<td>5 mg/kg IV once daily</td>
<td>IA</td>
</tr>
<tr>
<td></td>
<td>IV foscarnet or IV cidofovir</td>
<td>Foscarnet (90 mg/kg to 120 mg/kg daily)</td>
<td>IA</td>
</tr>
<tr>
<td></td>
<td>if intolerant to</td>
<td>Ganciclovir (5 mg/kg every two weeks)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ganciclovir or ganciclovir</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(38,39)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ganciclovir intraocular implant (40)</td>
<td>Implanted (release rate 1 µg/h to 2 µg/h) every six to nine months</td>
<td>IA</td>
</tr>
<tr>
<td></td>
<td>or foscarnet intraocular (41)</td>
<td>Foscarnet (2.4 mg once weekly)</td>
<td>IIB</td>
</tr>
<tr>
<td></td>
<td>Fomivirsen intraocular (42)</td>
<td>165 µg intraocular every two weeks</td>
<td>IA</td>
</tr>
</tbody>
</table>

*The doses of systemic medication listed are for patients with normal renal function. Patients with renal impairment may require dose reduction, as per the product monograph. †Recommended duration of induction treatment is a minimum of three weeks and should be continued until the CMV retinitis is quiescent. ‡For information regarding the duration of maintenance therapy, see the discussion in ‘Discontinuation of CMV retinitis maintenance therapy’ located in the text.

IV Intravenous
Recommendations

- Discontinuation of maintenance therapy can be considered in patients taking HAART who have had a CD4 count greater than 100 cells/µL for longer than six months (evidence grade IIIB) (8,11,50). The decision to discontinue therapy should also take into account the patient's HIV viral load, the anatomical location of retinal lesions, the remaining vision in both eyes, the feasibility of regular ophthalmological follow-up and adherence and adverse events related to both HAART and anti-CMV therapy (evidence grade IIB) (11). The patient, ophthalmologist and primary HIV-treating physician should be consulted when making this decision.

- Patients who discontinue anti-CMV therapy should be monitored closely for changes in immune status or recurrence of CMV disease (evidence grade IIC). CMV retinitis progression occasionally occurs despite sustained response to HAART (51). Patients should be made aware that recurrence warrants prolonged anti-CMV therapy (evidence grade IIB) (51).

- Reinitiation of maintenance therapy should be considered when the CD4 count falls below 100 cells/µL (evidence grade IIIB) (11).

Nonocular CMV disease

Nonocular CMV disease is uncommon. There is insufficient evidence to support maintenance therapy after induction with an anti-CMV drug. Nevertheless, many clinicians prescribe maintenance anti-CMV therapy when the disease is serious or recurrent.

GI CMV disease: The most frequent nonocular CMV disease is GI. Oral medication is not recommended because patients may have unreliable drug absorption.

Recommendations

- Patients with CMV GI disease should receive three weeks of therapy with IV ganciclovir or foscarnet (10,52) (see Table 5, induction therapy, for recommended dosing) (evidence grade IIIB).

- Chronic maintenance therapy is not recommended unless patients have a relapse following induction therapy (evidence grade IIIC) (52).

Other nonocular CMV diseases: Other nonocular CMV diseases are rare, and little data exist to support recommendations. Neurological disease is the second most frequent form of nonocular CMV disease.

Recommendations

- Patients with neurological CMV infection should receive three to six weeks of IV ganciclovir and/or foscarnet twice daily (evidence grade IIIB) (10,53). Patients who respond to induction therapy should be offered IV maintenance therapy (evidence grade IIA).

- Although ganciclovir has not been studied in neurological disease, the pharmacokinetic properties and efficacy of ganciclovir in CMV retinitis suggest that it may be an alternative to ganciclovir for this indication (evidence grade IIIB).
CONCLUSIONS

The management of CMV disease in HIV-infected patients has changed due to the introduction of HAART and oral anticytomegalovirus therapy. These guidelines are intended to help physicians treat HIV-positive patients with CMV disease based on current knowledge. Physicians expert in the care of HIV-positive patients should be involved in treatment decisions for these patients.

ACKNOWLEDGEMENTS: The workshops and the development of the guidelines were supported by an unrestricted grant from Hoffmann-La Roche Canada Inc.

REFERENCES

Group in collaboration with the AIDS Clinical Trials Group.


